港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

維立志博-B

65.000

-1.250-1.89%

成交量：112.63萬

成交額：7,440.92萬

市值：129.35億

市盈率：-32.37

高：70.000

開：70.000

低：63.900

收：66.250

52周最高：83.600

52周最低：57.450

股本：1.99億

香港流通股本：1.53億

量比：1.93

換手率：0.74%

股息：- -

股息率：- -

每股收益(LYR):-2.008

淨資產收益率：--

總資產收益率：--

市淨率：113.18

市盈率(LYR):-32.37

市銷率: - -

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

超42億美元！今日5款國產創新藥掀起出海熱潮

生物药大时代

維立志博-B藥品LBL-047成功出海獲3800萬美元首付款潛在收益高達10億美元

最高10億美元！和美國一家生物科技公司簽了個「獨家授權協議」！

維立志博-B(09887)就LBL-047與DIANTHUS簽訂全球獨家許可協議

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09887"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"維立志博-B","latestPrice":65,"timestamp":1760688489282,"preClose":66.25,"halted":0,"volume":1126318,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"已收盤","change":-1.25,"latestTime":"10-17 16:08:09","open":70,"high":70,"low":63.9,"amount":74409196,"amplitude":0.092075,"askPrice":65.2,"askSize":100,"bidPrice":65,"bidSize":5400,"shortable":0,"etf":0,"ttmEps":-1.858667,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1760923800000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":66.25,"openAndCloseTimeList":[[1760664600000,1760673600000],[1760677200000,1760688000000]],"volumeRatio":1.931207,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":1.931207,"shares":199000000,"dividePrice":0,"high":70,"amplitude":0.092075,"preClose":66.25,"low":63.9,"week52Low":57.45,"pbRate":"113.18","week52High":83.6,"institutionHeld":0,"latestPrice":65,"committee":0.963636,"eps":-2.008042,"divideRate":0,"volume":1126318,"delay":0,"ttmEps":-1.858667,"open":70,"prevYearClose":35,"prevWeekClose":69.9,"prevMonthClose":69.95,"prevQuarterClose":69.95,"fiveDayClose":69.9,"twentyDayClose":66.9,"sixtyDayClose":35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1757779200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-10-16","current":-34.971299,"percent":0.508772,"low":-50.052922,"twenty":-44.547984,"median":-42.195114,"eighty":-40.325333,"high":-37.26013,"avg":-42.543532,"sd":2.508734,"marketCap":13176581750},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-16","current":-42.061577,"twenty":-44.547984,"median":-42.195114,"eighty":-40.325333,"marketCap":13176581750}],"updateTime":1760694650117},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576700164","title":"超42億美元！今日5款國產創新藥掀起出海熱潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2576700164","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576700164?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 11:08","pubTimestamp":1760670502,"startTime":"0","endTime":"0","summary":"根据公告，Visara将在协议生效后的30个工作日内向AskGene Pharma支付700万美元的一次性、不可退还的首付款。目前，LBL-047已获美国新药临床试验许可及中国IND受理。该交易总金额最高可达10亿美元。许可人将获得8,000万美元首付款，并有资格根据该产品开发、注册审批和商业化进展收取最高14.5亿美元里程碑付款，以及未来潜在产品销售的分级特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017131410a6be3dd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017131410a6be3dd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1574","03692","BK1161","09887"],"gpt_icon":0},{"id":"2576995709","title":"維立志博-B藥品LBL-047成功出海 獲3800萬美元首付款 潛在收益高達10億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576995709","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576995709?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 10:28","pubTimestamp":1760668126,"startTime":"0","endTime":"0","summary":"维立志博-B（09887）发布公告，公司于2025年10月16日与DianthusTherapeutics,Inc.签订全球独家许可协议，双方将共同推进临床前资产及新型抗BDCA2-TACI双特异性融合蛋白LBL-047的开发。LBL-047已获得美国新药临床试验（IND）许可及中国内地IND受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510173537019885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2576195700","title":"最高10億美元！和美國一家生物科技公司簽了個「獨家授權協議」！","url":"https://stock-news.laohu8.com/highlight/detail?id=2576195700","media":"企业上市","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576195700?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 10:24","pubTimestamp":1760667892,"startTime":"0","endTime":"0","summary":"核心事件：南京维立志博生物科技公司在2025年10月16日，和美国一家叫Dianthus的生物科技公司签了个“独家授权协议”。维立志博能得到什么：首付款和近期里程碑款：最高3800万美元。其中包括2000万美元的“签字费”，2025年第四季度再付500万美元，以及最高1300万美元的近期研发进展奖金。未来潜在巨额奖金：如果这款药后续的临床开发、审批和商业化都成功了，维立志博最高还能拿到10亿美元的里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017113537a4645d5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017113537a4645d5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2575374928","title":"維立志博-B(09887)就LBL-047與DIANTHUS簽訂全球獨家許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2575374928","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575374928?lang=zh_tw&edition=fundamental","pubTime":"2025-10-16 20:55","pubTimestamp":1760619343,"startTime":"0","endTime":"0","summary":"本公司认为签订全球独家许可协议将加强本集团推进创新候选药物进入临床阶段以解决自身免疫疾病的承诺，并符合本公司及其股东的整体最佳利益。LBL-047以BAFF/APRIL和BDCA2为靶点，旨在同时抑制pDC的活性以及B细胞及浆细胞的分化及激活。LBL-047通过Fc区改造延长半衰期，可降低给药频次，提高患者依从性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)就LBL-047与DIANTHUS签订全球独家许可协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161"],"gpt_icon":0}],"pageSize":4,"totalPage":29,"pageCount":1,"totalSize":116,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/09887\",params:#limit:6,delay:false,,,undefined,":[]}}